Laboratorios Farmaceuticos Rovi, S.A.

Laboratorios Farmacéuticos Rovi, S.A. is a Spanish pharmaceutical enterprise that specializes in the research, development, manufacturing, and global commercialization of its own medicinal products. The company's operations span Spain, the European Union, OECD countries, and various international markets. In addition to its proprietary portfolio, Rovi also distributes pharmaceutical products under license from other laboratories. Its comprehensive product range addresses diverse medical requirements. Key offerings include Hibor and Enoxaparin biosimilar Becat, both low-molecular-weight heparins vital for the prevention and management of venous thromboembolic disease. Neparvis is prescribed for adult patients experiencing symptomatic chronic heart failure with reduced ejection fraction. To aid in the dietary management of hypercholesterolemia, Rovi provides Absorcol, Vytorin, and Orvatez. For the maintenance treatment of chronic obstructive pulmonary diseases (COPD), the company offers the long-acting bronchodilators Hirobriz Breezhaler and Ulunar Breezhaler. Volutsa assists men with benign prostatic hyperplasia (BPH) who exhibit moderate to severe storage and voiding symptoms and have not adequately responded to monotherapy. Furthermore, Medikinet and Medicebrán are available for the treatment of attention deficit hyperactivity disorder (ADHD) in pediatric and adolescent patients. Rovi also supplies an array of specialized hospital products for imaging diagnostics. These include contrast agents such as Iomeron and Iopamiro for computed tomography (CT) and interventional procedures; Multihance and Prohance for magnetic resonance imaging (MRI); and Sonovue for ultrasounds. The company additionally offers advanced contrast injection systems like EmpowerCTA+, EmpowerMR, and CT Exprès, along with their compatible disposable materials. Beyond its prescription medications, Rovi produces non-prescription pharmaceutical items and delivers contract manufacturing services to other businesses. These services encompass a wide spectrum of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves a broad clientele, including wholesalers, medical professionals, nursing staff, pharmacists, and directly to patients. Notably, Laboratorios Farmacéuticos Rovi, S.A. maintains a significant manufacturing collaboration with Moderna, Inc. for their mRNA COVID-19 vaccine candidate. Established in 1946 with its headquarters in Madrid, Spain, Laboratorios Farmacéuticos Rovi, S.A. operates as a subsidiary of Norbel Inversiones, S.L.